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Abstract
Background: The AP-1 transcription factor plays a major role in cell proliferation, apoptosis, differentiation and
developmental processes. AP-1 proteins are primarily considered to be oncogenic. Gene disruption studies placed
c-Jun as an oncogene at the early stage of a mouse model of hepatocellular carcinoma. Mice lacking c-Jun display
reduced number and size of hepatic tumors attributed to elevated p53 expression and increased apoptosis. This
suggests that c-Jun inhibition may serve as a therapeutic target for liver cancer. The c-Jun dimerization protein 2,
JDP2 is an AP-1 repressor protein that potently inhibits AP-1 transcription. On the other hand, the JDP2 locus was
found at a recurring viral integration site in T-cell lymphoma. We sought to examine the potential of JDP2 to
inhibit c-Jun/AP-1 oncogenic activity in mice. Towards this end, we generated a tetracycline inducible transgenic
mouse expressing JDP2 specifically in the liver. We used diethylnitrosamine (DEN) injection to initiate liver cancer
in mice and assessed the extent of liver cancer in JDP2-transgenic and wild type control mice by biochemical and
molecular biology techniques.
Results: JDP2-transgenic mice display normal liver function. JDP2-transgenic mice displayed potentiation of liver
cancer, higher mortality and increased number and size of tumors. The expression of JDP2 at the promotion stage
was found to be the most critical for enhancing liver cancer severity.
Conclusions: This study suggests that JDP2 expression may play a critical role in liver cancer development by
potentiating the compensatory proliferative response and increased inflammation in the DEN liver cancer model.
Background
Hepatocellular carcinoma (HCC) is the fifth most fre-
quent cancer. Approximately 500,000 cases of HCC are
diagnosed each year and it is the third leading cause of
cancer-related deaths [1]. The majority of cases of HCC
are due to hepatitis B virus, hepatitis C infections and
alcohol consumption [2]. During the course of chronic
infection, continuous intra-hepatic inflammation main-
tains a cycle of liver cell destruction and regeneration
that often terminates in HCC [3,4]. Various mouse
models for HCC were developed to study the molecular
mechanisms involved in various stages of liver cancer
[5]. These mouse models mimic the etiology of liver
cancer in man. Certain chemical carcinogens which
induce hepatocyte DNA damage can result in HCC.
Mice injected with a single injection of tumor initiator
diethylnitrosamine (DEN) results in liver cancer [6-8].
Inflammation is a known factor that plays a casual role
in cancer in general and liver cancer in particular [8-10].
AP-1 is one of the transcription factors found at the
receiving end of multiple signaling pathways. AP-1 is
composed of either homo or hetero dimers of basic leu-
cine zipper (bZIP) family members [11]. Dimerization is
required for specific binding to a DNA sequence known
as the TPA response element (TRE) found in the pro-
moter region of many genes. Although the role of AP-1
in cell proliferation is well established [12], activating
mutations of this complex have never been found in
human cancer. Most of the important insights regarding
the specific function of AP-1 proteins have been estab-
lished through the use of mice with either loss- or gain-
of-function manipulations of various members of the
bZIP protein family [13].
The most-studied member of the AP-1 family is c-Jun.
Despite its ability to transform chicken embryo fibro-
blasts, c-Jun over-expression alone does not result in
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c-Jun cooperates with Ha-Ras in cell transformation
[14]. In mice, c-Jun disruption causes embryonic lethal-
ity at midgestation. The affected embryos exhibit heart
defects and arrested liver development [15]. Conditional
c-Jun knockout in the liver of adult mice prevents the
appearance of HCC in the DEN liver cancer model,
implicating c-Jun as a crucial player in the initiation
steps of liver carcinogenesis [16].
The c-Jun dimerization protein 2, JDP2, encodes an 18
kDa bZIP protein that interacts with c-Jun [17]. JDP2
can bind TRE DNA elements as well as the cyclic AMP
response element (CRE) as a homo- or hetero dimer
[17,18]. Upon dimerization with c-Jun, DNA binding is
potentiated, but the transcription is inhibited [17]. JDP2
inhibits transcription by multiple mechanisms [17,19].
JDP2 is involved in cell differentiation processes, such as
differentiation of skeletal muscle cells [20], osteoclasts
[21] and in stress response to ultraviolet irradiation [22].
Various studies suggest that JDP2 has a dual role in
malignant transformation. On the one hand, it is well
established that JDP2 counteracts AP-1 transcription
[17], and thus may interfere with the oncogenic proper-
ties of c-Jun. JDP2 has been found to inhibit cell trans-
formation induced by Ras in vitro and in xenografts
injected into SCID mice [23]. On the other hand, JDP2
has been identified as a candidate oncogene in a high-
throughput screen based on viral insertional mutagen-
esis in mice [24-26]. Serial analysis of gene expression
identified increased levels of JDP2 in a number of can-
cers including prostate, kidney, liver and skeletal muscle
http://www.genecards.org/cgi-bin/carddisp.pl?gen-
e=JDP2&search=JDP2. In order to examine whether
JDP2 increased expression may be a coincidence or may
play a role in liver cancer development, we have gener-
ated transgenic mice with liver specific JDP2 expression
and examined the consequence in a chemically induced
liver cancer model. We found that JDP2 increases liver
cancer severity and that JDP2 expression at the promo-
tion stage is most important for this activity.
Results
To establish the role of JDP2 over-expression in hepato-
cellular carcinoma, we have generated a tetracycline
regulated JDP2 responder transgenic mouse line [27].
HA-JDP2 and the b-Galactosidase reporter are co-
expressed under the control of the tetracycline regulator
(Figure 1A). A mouse line showing germ line transmis-
sion was crossed with a LAP-driver mouse line expres-
sing the tetracycline transactivator (tTA) in the liver
[28]. Mice crosses were performed between matched
gender homozygous LAP-driver mice and JDP2-hetero-
zygous transgenic mice. Mice positive for both JDP2
transgene and tTA (Figure 1B) are expected to express
HA-JDP2 in hepatocytes and are further designated
JDP2-transgenic. The mating resulted the expected 50%
Mendelian distribution of JDP2-transgenic (tg) and con-
trol tTA transgene (wt). Since male mice are more sus-
ceptible to liver cancer in the DEN model [29], all
experiments described were performed with male mice.
To study the HA-JDP2 specific expression in the liver,
JDP2-transgenic mice were sacrificed and lysates derived
from different tissues were separated by SDS-PAGE fol-
lowed by Western blotting with either anti-HA or anti-
JDP2 antibodies (Figure 1C). Whereas a strong cross
reactive band at the expected 24 kDa size was observed
with lysate derived from liver of JDP2-transgenic, no
expression was observed in the liver of wild type mice.
In addition, lysate derived from heart, lung and spleen
of JDP2-transgenic mice did not display expression of
the transgene however, endogenous JDP2 expression is
readily observed at the expected 18 kDa size. Lysate
derived from kidney, displayed a very low level of
expression of the HA-JDP2 transgene (Figure 1C, anti-
HA). Consistently, b-galactosidase activity of cell lysates
derived from different tissues of JDP2-transgenic mice
displayed high activity in the liver and at least 10 fold
lower b-galactosidase activity was measured in the kid-
ney and negligible activity was observed in heart, lung
and spleen (Figure 1D). The LAP-tet driver mouse uti-
lizes a tet-off system, namely, transgene expression is
shut-off in the presence of doxycycline. Indeed, supple-
mentation of doxycycline (0.2 mg/ml) resulted in com-
plete loss of HA-JDP2 expression (Figure 1E).
We first examined the effect of JDP2 expression on
liver pathophysiology. JDP2 is highly expressed in the
nuclei of JDP2-transgenic hepatocytes (Figure 2A, left
panel). The liver/body weight ratio is similar between
JDP2-transgenic and wild type animals (Figure 2B).
Similarly, serum alanine aminotransferase (ALT), a mar-
ker for hepatocyte damage, is not significantly altered
between the genotypes (Figure 2C). We also measured
the extent of apoptotic cells and hepatocyte prolifera-
tion by TUNEL and PCNA staining of liver sections
and revealed no significant difference between the geno-
types (Figure 2A). To reveal the expression level of sev-
eral bZIP proteins and cell cycle regulators, we used
real time PCR (qPCR) with cDNA derived from mRNA
isolated from one month old mice. This analysis
revealed that most of the genes tested were not signifi-
cantly altered in cDNA derived from the JDP2-trans-
genic as compared with their wild type control (Figure
2D). c-Jun is the only gene whose transcription is mod-
estly up-regulated. This was not expected, since c-Jun
was previously described to be downregulated by JDP2
[19]. Collectively, mice with JDP2 over-expression in
hepatocytes display no significant change in liver
function.
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Page 2 of 14Figure 1 Liver specific expression of JDP2 in JDP2-transgenic and control mice. A. HA-JDP2 expressing mice responder line was generated
in the pBIG bi-cistronic expression plasmid under the regulation of tetracycline response elements. The promoter co-regulates the expression of
the b-galactosidase reporter together with HA-JDP2 protein. tTA-responder mice express the tetracycline activator (tTA) under the control of
Liver Activating Protein promoter (LAP). tTA is expressed specifically in hepatocytes. The association of the tTA with the DNA is prevented in the
presence of doxycycline thus results in shut-off transgene expression. B. Mouse tail genotyping by PCR was performed with specific
oligonucleotides corresponding to the tTA driver (tTA, right panel) and JDP2-transgene (JDP2, left panel). DNA derived from either double
transgenic mouse, JDP2-transgenic (lanes 1) or control wild type mouse (lanes 2) was used. Lanes 3 no DNA was added to the PCR mix. C.
Western blot analysis with nuclear extract derived from the indicated tissues of JDP2-transgenic mouse (tg) and liver lysate from wild type
mouse (wt). Membranes were probed with anti-JDP2 antibody (top panel) anti-HA antibody (middle panel) and anti-a-tubulin antibody (bottom
panel) was used as loading control. The migration of HA-JDP2 transgene and endogenous JDP2 protein is indicated by an arrow at the right
side of the top panel. D. b-galactosidase activity with cell lysate derived from the indicated tissues of JDP2-transgenic mouse. The O.D. value at
420 nm is shown. E. Western blot analysis with liver nuclear cell lysate derived from either wild type (wt) or JDP2-transgenic (tg) mice either
untreated (-dox) or treated with doxycycline (+dox, 0.2 mg/ml) for 3 days. Membrane was probed sequentially with anti-JDP2 (top panel)
followed by anti-a-tubulin (bottom panel) as loading control.
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Page 3 of 14Figure 2 JDP2 expression does not alter liver pathophysiology. A. Immunohistochemistry of liver sections derived from either wild type (wt)
or JDP2-transgenic (tg) mice. The expression of HA-JDP2 transgene was analyzed with anti-JDP2 antibody (left panel). The extent of apoptotic
and proliferation of hepatocytes was analysed by TUNEL assay (middle panel) and PCNA staining (right panel). Arrows indicate positively stained
cells. Liver/body weight ratio (B.) and Serum ALT (C.) was determined from one month old of either wild type control (wt, black bar) or JDP2-
transgenic (tg, grey bar) mice. The results represent the average and SEM of the indicated number of animals (n). D. Real time qPCR of the
indicated selected genes was performed from cDNA derived from mRNA extracted from liver of wild type and JDP2-transgenic mice. The results
represent the calculated expression ratio between JDP-transgenic divided by the expression of the corresponding gene of the wild type mice.
The average and SEM of three different experiments performed with pooled mRNA from at least three mice is presented.
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Page 4 of 14To reveal the role of JDP2 expression in hepatocytes
in a liver cancer model, we used a well established che-
mical carcinogen induced liver cancer protocol. In this
model the tumors are initiated by the genotoxic drug
diethylnitrosamine (DEN, 100 mg/Kg) at four weeks of
age followed by tumor promoter Phenobarbital since
eight weeks of age (Figure 3A). We first followed mice
survival (Figure 3B). Whereas in wild type control mice
70% of the mice survived, within the first sixteen weeks
of age, in JDP2-transgenic only 40% of the mice sur-
vived. Beyond four months of age, no further deaths
were recorded. Dead mice did not display any sign of
liver cancer. The precise cause of death was not deter-
mined. Surviving mice were sacrificed at seven months
of age and their liver was analyzed. Wild type mice dis-
played 5.3% of liver/body weight, whereas, liver derived
f r o mJ D P 2 - t r a n s g e n i cm i c eh a dar e l a t i v e l ye n l a r g e d
liver corresponding to 9.5% liver/body weight (Figure
4A). Serum ALT levels were significantly higher in
JDP2-transgenic mice (ALT-300 u/l) compared with
wild type mice which had similar ALT levels as com-
pared to one month old non-injected mice (Figure 4B).
Nine out of ten JDP2-transgenic mice that survived
beyond four months of age displayed numerous
(between 1-8) visible macroscopic tumors (diameter
between 0.3-1.5 cm) while only one out of sixteen liver
derived from control wild type mice displayed one
macroscopic tumor (Figure 4C). All other fifteen wild
type mice showed no visible tumors at seven months of
age. H&E stained liver sections demonstrated the exis-
tence of large tumors in JDP2-transgenic mice while in
the control wild type mice only small nodules were
readily observed (Figure 4D). Collectively, using the four
weeks DEN liver cancer model, the JDP2-transgenic
mice displayed a significantly lower survival rate and
increased severity of liver cancer disease.
One possible explanation for the increase in disease
severity in JDP2-transgenic mice might be that JDP2
expression potentiates tumor initiation. To examine
JDP2’s role in tumor initiation, mice were injected by a
single DEN injection (100 mg/Kg) at four weeks of age.
Mice were sacrificed 24 h and 48 h following injection
and liver damage was assessed. Indeed, following DEN
injection liver damage was increased by twofold as
observed by the ALT level in both wild type and JDP2-
transgenic mice but with no significant difference
between the two genotypes (Figure 5A). In addition,
liver to body weight was not significantly altered in both
genotypes (Figure 5B). Gene expression profile of
numerous selected genes was un-affected 24 h following
Figure 3 Survival curve for the four weeks DEN protocol. A. Schematic diagram is depicted for the four weeks DEN protocol. Mice were
injected at four weeks of age with a single DEN injection (100 mg/Kg). At eight weeks of age the tumor promoter, 0.07% phenobarbital was
provided in the drinking water in 5% sucrose. B. Mice survival was followed until eleven months of age. The survival of wild type (n = 23, dotted
line) versus JDP2-transgenic (n = 24, solid line). Kaplan-Meier analysis performed shows P value < 0.05.
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Page 5 of 14Figure 4 Liver pathology of eleven months old DEN injected mice. Liver/body weight ratio (A.) and Serum ALT (B.) was determined from
eleven months old of either wild type control (wt) or JDP2-transgenic (tg) mice. The results represent the average and SEM of the indicated
number of animals (n). C. The number of macroscopic tumors (Y axis) and their corresponding size are drawn for each mouse (X axis). The circle
size corresponds to the tumor diameter according to the centimeter scale provided at the bottom of the figure. Student’s t-test P value < 0.01
D. H&E staining of representative liver sections of DEN injected eleven months old either wild type control (wt) or JDP2-transgenic (tg).
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Page 6 of 14Figure 5 JDP2 role in tumor initiation following DEN injection. Mice were either not treated (0 h) or injected with DEN 100 mg/Kg and
sacrificed 24 h and 48 h following injection. Serum ALT (A.) and Liver/body weight ratio (B.) were determined in wild type (wt, black bar) and
JDP2-transgenic (tg, grey bar). The results represent the average and SEM of the indicated number of animals (n). C. The expression level of the
indicated genes was determined by Real time qPCR to the indicated selected genes from cDNA derived from mRNA prepared from liver tissue
of either wild type control (wt) or JDP2-transgenic (tg). The expression level of each gene was normalized by the 18s ribosomal RNA and b2-
microglobulin mRNA. The mRNA derived from either non-injected (taken from data set Figure 2D) or mice injected with DEN (100 mg/Kg)
sacrificed 24 h thereafter. The results represent the calculated expression ratio between JDP-transgenic divided by the expression level of the
corresponding gene in the wild type mice. The average and SEM of three different experiments performed with pooled mRNA from the 0 h-n
[tg = 4/wt = 5] and 24 h-n [tg = 3/wt = 2] animals.
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Page 7 of 14DEN injection between wild type and JDP2-transgenic
(Figure 5C). To examine the changes that occur during
liver promotion stages, mice were injected with DEN at
four weeks of age treated with Phenobarbital at eight
w e e k so fa g e .M i c ew e r es a c r i f i c e da tf o u rm o n t h so f
age. Liver/body weight ratio was twofold higher in
JDP2-transgenic mice compared with age matched DEN
injected wild type control mice (Figure 6A). In addition,
serum ALT levels were six fold higher in JDP2-trans-
g e n i cm i c ea l r e a d ya tf o u rm o n t h so fa g e( F i g u r e6 B ) .
We analyzed the pattern of gene expression of selected
genes by qPCR. Surprisingly, JDP2-transgenic mice dis-
played potentiation of expression of numerous genes
including: ATF3, CHOP10, cFos and JunD (Figure 6C).
In addition, inflammatory cytokines such as IL-1, IL-6
and TNFa were highly elevated. Moreover, p53 mRNA
Figure 6 Gene expression profile of DEN injected mice at four months of age. Liver/body weight ratio (A.) and serum ALT (B.) were
determined in wild type mice (wt, black bar) and JDP2-transgenic mice (tg, grey bar). The results represent the average and SEM of the
indicated number of animals (n). C. The expression level of the indicated genes was determined by Real time qPCR to the indicated selected
genes from cDNA derived from mRNA prepared from liver tissue of either wild type control (wt) or JDP2-transgenic (tg). The expression level of
each gene was normalized by the 18s ribosomal RNA and b2-microglobulin mRNA. The mRNA derived from mice injected with DEN at four
weeks of age followed by Phenobarbital treatment from eight weeks of age sacrificed at four months of age. The results represent the
calculated expression ratio between JDP2-transgenic (tg) divided by the expression level of the corresponding gene in the wild type mice (wt).
The average and SEM of three different experiments performed with pooled mRNA from n [tg = 4/w = 3] animals.
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Page 8 of 14level and its target genes p21 and Mdm2 transcription
level were significantly increased in the liver of JDP2-
transgenic mice (Figure 6C). c-Jun expression was not
altered as compared with one month old non-injected
mice. Collectively, the data suggests that a dramatic
increase in the expression of key regulatory proteins
occurs in JDP2-transgenic mice during the tumor pro-
motion stage.
To assess the role of JDP2 in a different DEN induced
liver cancer protocol, we used a second well established
protocol in which a single injection of DEN (25 mg/Kg)
at 14 days postnatal [8]. Unlike the four weeks DEN
protocol, mice treatment at the earlier age does not
require the assistance of tumor promoter to develop
liver cancer. Using this model 100% of injected mice
develop macroscopic liver tumors at eleven months of
age [8]. To identify the importance of the time of JDP2
expression at the different stages of the development of
liver cancer, we took advantages of the ability to shut-
off the transgene expression using doxycycline. We stu-
died three groups of mice in which JDP2 expression was
shut-off during different stages of liver cancer develop-
m e n t :i n i t i a t i o n( F i g u r e7 A ,g r o u pB ) ,i n i t i a t i o n+p r o -
motion (Figure 7A, group C) and progression (Figure
7A, group D). Wild type control mice receiving identical
doxycycline treatment were included in each of the
three experimental cohorts.
Consistent with the four weeks DEN protocol, mice
expressing JDP2 in the liver displayed increased disease
severity. Both serum ALT levels and liver/body weight
ratio were significantly higher in JDP2-transgenic mice
as compared with wild type mice (Figure 7B and 7C;
group A). The number of macroscopic tumors was
doubled in JDP2-transgenic mice as compared with the
wild type mice (Figure 7D; group A). In addition, the
tumors derived from the JDP2-transgenic mice were big-
ger as compared with wild type control mice. Represen-
tative macroscopic and microscopic tumors are shown
(Figure 8A and 8B). In addition, some of the JDP2-
transgenic mice displayed lung metastases (Figure 8C).
Collectively, using the 14 day DEN protocol, JDP2-trans-
genic resulted in an increase in the severity of liver can-
cer. Similar results were obtained with mice that were
either treated with doxycycline during pregnancy
through three weeks postnatal (Group B) or mice that
were treated with doxycycline from seven months of age
(group D). Interestingly, JDP2-trangenic mice treated
with doxycycline from pregnancy till seven months
(Group C) displayed similar ALT level and comparable
number of tumors to wild type control mice (Figure
7D). Western blot analysis of liver lysates derived from
all four experimental groups revealed that doxycycline
treatment resulted in complete loss of transgene expres-
sion (Figure 8D group D). Moreover, JDP2 expression
was observed in the liver and tumors derived from
JDP2-transgenic mice. This result suggesting, that liver
tumors observed in JDP2-transgenic do not represent
hepatocyte that lost JDP2 expression. Whereas, lack of
expression of JDP2 either at the initiation stage or the
progression stages had no effect on the disease severity,
t h el a c ko fJ D P 2e x p r e s s i o nd u r i n gt h ei n i t i a t i o na n d
promotion stage significantly reduced the number of
tumors and severity of the disease. These results suggest
that the expression of JDP2 during the promotion stage
plays a critical role in the increased severity of liver can-
cer in this model.
Discussion
The role of JDP2 in carcinogenesis is a matter of debate.
On the one hand, JDP2 over-expression results in cell
cycle arrest [20] and reduced foci formation in Ras
dependent cell transformation [23]. In addition, prostate
cancer cell lines with JDP2 over-expression form smaller
tumors in mice [23]. On the other hand, JDP2 over-
expression in chicken embryo fibroblasts imparts a par-
tial oncogenic phenotype [30]. Moreover, JDP2 locus
was identified at viral integration sites resulting in T cell
lymphoma [24-26,31]. Most of JDP2 proteins that are
expressed as a result of the viral integration lack the N-
terminal JDP2 domain, yet some integrations enhance
the expression of full length JDP2 [25,31]. The mechan-
isms through which JDP2 acts as an oncogene remain to
be determined. In addition, whether or not JDP2 plays a
role in carcinogenesis in humans is yet to be
demonstrated.
Here we described the generation of JDP2-transgenic
mice that express JDP2 specifically in the liver. Although
JDP2-expressing mice highly express JDP2, JDP2-trans-
genic mice display no liver dysfunction phenotype unless
faced with specific perturbations such as DEN adminis-
tration. Thus, c-Jun inhibition by JDP2 during preg-
nancy is effective only from day 10-12 and therefore
may bypass the critical timing resulting in the adverse
effect of inhibition of fetal liver development. Similar
results were obtained with dominant negative IkB trans-
genic mice that were able to complete full term and still
efficiently inhibit NFkB activity in adult mice [32]. It
appears that the LAP promoter that is driving the
expression of the tTA is expressed at extremely low
levels in utero. Therefore, the transgene expression is
insufficient to completely inactivate either NFkB or c-
Jun both of which are required for liver development.
c-Jun was found to promote liver cancer. Mice with c-
Jun conditional knockout in the liver display reduced
liver cancer development following the well established
DEN model. c-Jun-KO mice displayed increased apopto-
sis in the liver. c-Jun was suggested to act through a
p53 dependent mechanism and activation of the pro-
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Page 9 of 14Figure 7 JDP2-tg and liver cancer in 14 days DEN protocol. Mice were injected with DEN 25 mg/Kg at 14 days postnatal and sacrificed at
eleven months of age. A. Schematic diagram representing the 14 day DEN protocol and doxycycline treatments used in the indicated
experimental groups. Mice were treated with doxycycline 0.2 mg/ml dissolved in 5% sucrose in the drinking water as indicated in the scheme
(black line, no JDP2 expression). Grey line represents JDP2 expression. Serum ALT (B.) and Liver/body weight ratio (C.) was determined. The
results represent the average and SEM of the indicated number of animals (n). D. The number of macroscopic tumors in liver derived from
eleven months old mice injected with DEN and treated as depicted schematically for each experimental group. Wild type (wt, black bar) and
JDP2-transgenic (tg). The results represent the average and SEM of the number (n) of animals in each group. Asterisks represent P values < 0.05
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Page 10 of 14apoptotic gene Noxa [16]. Previous studies directed
towards inhibition of c-Jun transcription activity used c-
Jun lacking its transcription activation domain, TAM67.
Indeed, expression of TAM67 in the skin resulted in
inhibition of tumor promotion in two stage skin carci-
nogenesis model [33]. JDP2 was previously shown to
inhibit cell proliferation in vitro and directly inhibit the
transcription of cell cycle proteins such as cyclin D1
[20]. In view of these results, we expected that JDP2
over-expression in the liver will mimic c-Jun disruption
and thus may result in inhibition of liver cancer devel-
opment in this model. In contrast, JDP2 potentiated the
severity of liver cancer in the two DEN induced hepato-
cellular cancer models. JDP2-transgenic mice displayed
numerous enlarged visible tumors and higher liver/body
ratio as well as increased level of liver damage. Gene
Figure 8 Liver tumors analysis for 14 days DEN protocol. A. Representative liver photos derived from either wild type control (wt) and JDP2-
transgenic (tg) mice are shown. B. Liver sections stained with H&E of either wild type or JDP2-tg. C. Lung section with metastatic liver tumor
derived from JDP2-tg mice is shown. D. Western blot analysis of lysate derived from eleven months old mice of either wild type (wt 1-2, lanes 5-
7) or JDP2-transgenic (tg 1-2, lanes 1-4) mice. Lysate was prepared from liver (non Tm, lanes 1-2 and 5-6) and liver tumors (Tm, lanes 3-4 and 7)
from the same mouse cohort (indicated by a number) of the doxycycline treated mice as shown in A. Tumors were extracted only from wild
type mice #1 representing the different experimental groups. Membranes were probed with anti-JDP2 (top lane in each experimental group)
and anti-a-tubulin (bottom lane in each experimental group).
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Page 11 of 14expression analysis revealed an increase in the inflam-
matory response at four months old JDP2-transgenic
mice. Interestingly, CHOP10 is expressed at high levels
in JDP2-transgenic mice. We have demonstrated that
JDP2 can act as a strong transcription activator depend-
ing on the leucine zipper protein member it is asso-
ciated with. CHOP10 protein can form stable
heterodimer with JDP2 and is found to activate tran-
scription from TRE dependent genes [34]. Indeed,
CHOP10 expression level is highly induced in mice
injected with DEN during the promotion stage as well.
The mechanism by which CHOP10 expression is aug-
mented is yet to be determined. The potentiation of
TRE dependent genes such as those elevated during the
promotion stage in JDP2-trangenic mice could be the
result of JDP2-CHOP10 transcription activity. In addi-
tion to CHOP10, ATF3 expression level is highly ele-
v a t e di nt h el i v e ro ff o u rm o n t h so l dJ D P 2 - t r a n s g e n i c
mice. Interestingly, both CHOP10 and ATF3 were iden-
tified as JDP2 target genes [35,36]. ATF3 was found to
act as an oncogene in breast tumors [37]. Therefore,
ATF3 high expression levels observed in the liver of
JDP2-transgenic mice may a play a positive role at the
tumor promotion stage of liver cancer.
The mechanism by which the impaired HCC develop-
ment following c-Jun disruption was proposed to be due
increased hepatocyte apoptosis in a cell autonomous
manner [16]. In contrast, using the DEN model in mice
with liver disruption of IKKb, it appears that hepatocyte
death is the main driving force that promotes cell prolif-
eration leading to liver cancer development in a non cell
autonomous manner [8]. Retroviral activation of JDP2 in
T-cell lymphomas of mice is the only evidence for a gain-
of-function potential of JDP2 in cancer development.
Although the fact that most of the resulted JDP2 tran-
scripts lacks the N-terminal histone acetylation inhibitory
(INHAT) domain [38], some tumors represent elevation
of canonical full length JDP2 transcript [31]. Expression
of low levels of JDP2 together with mutant NRas (G12D)
resulted in anchorage independent growth [31]. In con-
trast, JDP2 over-expression resulted in inhibition of Ha-
Ras dependent foci formation in NIH3T3 [23]. It was
postulated that high JDP2 expression level results in a
cellular toxicity and therefore, inhibited cellular transfor-
mation by Ras. However, in the liver such cellular toxicity
may serve as the driving force in potentiating liver cancer
through compensatory proliferation mechanism [10].
Collectively, it seems that JDP2 plays a protective role in
a cell autonomous manner in vitro but the same process
can have a positive outcome in a non cell autonomous
way resulting in potentiation of liver cancer.
To examine whether or not JDP2 has an effect at the
tumor initiation stage, we tested the expression of genes
24 h following DEN injection. The expression of
numerous genes revealed no significant alteration of
expression between wild type and JDP2 transgenic mice.
This suggested that liver damage and tumor initiation is
alike in mice independent of JDP2 expression. Consis-
tently, JDP2-transgenic mice in which transgene expres-
sion was suppressed during the first three weeks of life
displayed very similar liver cancer severity as compared
with a mice cohort in which JDP2 was expressed at all
stages. In contrast, mice in which JDP2 expression was
suppressed during the initiation and promotion stages
showed similar liver cancer levels as compared with wild
type mice. Collectively, JDP2 expression during the pro-
motion stage is found to be important for potentiation
of liver cancer by acting as a tumor promoter in the
DEN model.
Conclusions
JDP2 over-expression potentiaes DEN induced liver can-
cer development. JDP2 role at the promotion stage is
demonstrated. The increase of CHOP10 expression may
provide a possible explanation for JDP2 potentiation of
gene transcription at the promotion phase of liver can-
cer development. Collectively, JDP2 plays a dual role in
carcinogenesis depending on the cellular and tissue
context.
Methods
Transgenic Mice
All studies involving mice were performed according to
the protocol approved by the Technion Animal Inspec-
tion Committee. The Technion holds an NIH animal
approval license, number A5026-01.
Mice strain
LAP mice
Mouse strain with tetracycline activator (tTA) liver
expression under the control of a tissue-specific C/EBPb
(LAP) promoter [28]. The system represents the Tet-off
system. Doxycycline hydrochloride (D-9891, Sigma-
Aldrich) 0.2 mg/ml is dissolved in 5% sucrose and sup-
plied in the drinking water to counteract the bitter taste
of the antibiotic.
JDP2 transgenic mice
The tet-promoter is designed to drive bi-directionally
the expression of b-galactosidase gene and HA-JDP2
[27]. Crossing the homozygous LAP-driver with the het-
erozygous JDP2-responder, single copies of the tTA and
JDP2 are present in the double transgenic mice (JDP2-
t r a n s g e n i c ,t g ) ,a n das i n g l ec o p yo ft h et T At r a n s g e n e
(control, wt).
Mouse Genotyping
Mouse genotyping is routinely performed by PCR on
genomic DNA extracted from mouse tail (XNAT,
Sigma-Aldrich). PCR Primers used for genotyping:
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cagctgctcc, tTAF gctgcttaatgaggtcgcaatcg, tTAR gcccca-
cagcgctgagtgcat. PCR was performed using RedyMix™
reaction mix (R2648, Sigma-Aldrich)
DEN protocol
Mice were injected intraperitoneally with DEN either
with 25 mg/Kg at two weeks of age or 100 mg/Kg at
four weeks of age followed by addition of 0.07% pheno-
barbital in the drinking water containing 5% sucrose at
eight weeks of age.
Blood analysis
Blood samples were rapidly taken from the heart of
anesthetized mice. Serum was separated and alanine
aminotransferase (ALT) level was determined at the Bio-
chemistry Department Rambam Medical Center.
Harvesting mouse liver
Livers were excised from anesthetized animals. Exter-
nally visible nodules and tumors were counted and mea-
sured. Part of the liver was fixed in 4% buffered
formaldehyde and paraffin embedded for histological
analysis, and the remaining liver tissue was quickly fro-
zen in liquid nitrogen and stored at -80°c until use.
Immunohistochemical Analysis
Tissue sections (6 μm) were stained with Hematoxylin
and Eosin (H&E) for general morphology or with anti-
bodies against JDP2 [17] and PCNA (Santa-Cruz, SC-
7907). Immunostaining was performed using the EnVi-
sion™ G\2 System alkaline phosphatase kit (DakoCyto-
mation K5355, Dako). Staining was performed according
to the manufacturers’ instructions. Sections were visua-
lized using an Olympus light microscope.
Apoptosis was determined by the TUNEL staining kit.
Sections were stained by the in situ death detection
POD kit (Roche Diagnostics). Proliferation was deter-
mined by anti-PCNA staining (Santa-Cruz, SC-7907).
Statistical Analysis
Data are expressed as means ± SEM in n number of
experiments. Differences were analyzed by Student’st
test. P values < 0.05 were considered significant. Overall
survival analysis was studied by Kaplan-Meier curves.
Nuclear Extract and Western blotting
Western blotting with liver nuclear protein extract was
performed as previously described [34].
JDP2 [17] and anti-HA antib o d i e sw e r eu s e da t1 : 5 0 0
dilution, anti-a-tubulin (Sigma-Aldrich) was used at
1:5000 dilution.
mRNA analysis
RNA was extracted from 30 mg liver tissue using RNeasy
Kit according to the manufacturers’ instructions (Qiagen
Inc.). Single-stranded cDNA were synthesized by reverse
transcription using Verso™ cDNA Kit (Thermo Scientific
AB-1453/A) with random hexamer primer. Prior to cDNA
preparation samples were incubated at 70°C for 5 minutes.
Real-time qPCR was performed with the Rotor-Gene
6000TM (Corbett) using absolute blue SYBER green ROX
mix (Thermo Scientific AB-4162/B). Values were normal-
ized with 18s and b2-microglobulin levels for each sample.
Primer sequences are provided:
Sequence - Primer Name
TNF-a- F-ccagaccctcacactcagatca R-cacttggtggtttg
ctacgac
18s - F-tagagggacaagtggcgttca R-cccggacatctaagggcat
Jun-D - F-ggcgggattgaaaccaggg R-agcccgttggactgga
tga
IL-1 - F-gcaccttacacctaccagagt R-aaacttctgcctgacga
gctt
Myd88 - F-aggacaaacgccggaactttt R-gccgatagtctgtct
gttctagt
p21 - F-cgagaacggtggaactttgac R-cagggctcaggtagac
cttg
Mdm2 - F-aggagatgtgtttggagtccc R-ctcagcgatgtgccag
agtc
Noxa - F-gcagagctaccacctgagttc R-cttttgcgacttccca
ggca
p53 - F-ctctcccccgcaaaagaaaa R-ctcctctgtagcatgggcatc
CHOP10 - F-gggccaacagaggtcacac R-cttcatgcgttgc
ttccca
IL-6 - F-tagtccttcctaccccaatttcc R-ttggtccttagccact
ccttc
c-Jun - F-ccttctacgacgatgccctc R-ggttcaaggtcatgctc
tgttt
JUNB - F-tcacgacgactcttacgcag Rccttgagaccccgata
ggga
JDP2 - F-ctcactcttcacgggttgg R-gctgaaatacgctgacatc
fos - F-ccagcagaagttccgggtag R-gtagggatgtgagcgtggata
CycD1 - F-gcgtaccctgacaccaatctc R-ctcctcttcgcacttc
tgctc
ATF3 - F-gaggattttgctaacctgacc R-ttgacggtaactgactccc
b2-microglubulin - F-ttctggtgcttgtctcactga R-cagt
atgttcggcttcccattc
List of abbreviation
ALT: Alanine aminotransferase; AP-1: Activating protein 1; ATF3: Activating
transcription factor 3; bZIP: basic leucine zipper; CHOP10: C/EBP homologous
protein 10; DEN: diethylnitrosamine; HCC: Hepatocellular carcinoma; IkB:
Inhibitor of kB; IKKb: IkB kinase b; JDP2: c-Jun dimerization protein 2; LAP:
liver activating protein; NFkB: Nuclear factor kB; tTA: tetracycline
transactivator.
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